33766087fb19a7f4fa088a11e72e86da2d094701
FBXO11.md
| ... | ... | @@ -2,6 +2,8 @@ |
| 2 | 2 | bibliography: 'morinlab.bib' |
| 3 | 3 | csl: 'NLM.csl' |
| 4 | 4 | link-citations: true |
| 5 | +nocite: | |
|
| 6 | + @parryWholeExomeSequencing2013, @richterRecurrentMutationID32012, @hubschmannMutationalMechanismsShaping2021, @arthurGenomewideDiscoverySomatic2018 |
|
| 5 | 7 | --- |
| 6 | 8 | [[_TOC_]] |
| 7 | 9 | |
| ... | ... | @@ -13,11 +15,7 @@ These mutations present a potential novel target for therapeutic intervention, p |
| 13 | 15 | |
| 14 | 16 | ## Relevance tier by entity |
| 15 | 17 | |
| 16 | -|Entity|Tier|Description | |
|
| 17 | -|:------:|:----:|--------------------------| |
|
| 18 | -||2|relevance in MZL not firmly established[@parryWholeExomeSequencing2013]| |
|
| 19 | -| |1 |high-confidence BL gene [@richterRecurrentMutationID32012]| |
|
| 20 | -| |1 |high-confidence DLBCL gene[@hubschmannMutationalMechanismsShaping2021; @arthurGenomewideDiscoverySomatic2018]| |
|
| 18 | +[[include:table1_FBXO11]] |
|
| 21 | 19 | |
| 22 | 20 | ## Mutation incidence in large patient cohorts (GAMBL reanalysis) |
| 23 | 21 |